AQR Capital Management
CYCN icon

AQR Capital Management’s Cyclerion Therapeutics CYCN Stock Holding History

AQR Capital Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,113
Closed -$191K – 2204
2020
Q4 		$191K Buy
+3,113
New +$212K ﹤0.01% 2095
2020
Q3 		– Sell
-3,940
Closed -$466K – 2198
2020
Q2 		$466K Sell
3,940
-4,204
-52% -$352K ﹤0.01% 1768
2020
Q1 		$432K Buy
8,144
+776
+11% +$55.4K ﹤0.01% 1634
2019
Q4 		$401K Buy
+7,368
New +$688K ﹤0.01% 1823

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AQR Capital Management's CYCN Position: Q1 2021 in Review

AQR Capital Management sold out of Cyclerion Therapeutics (CYCN) in Q1 2021, closing a stake of 3,113 shares — an estimated $191K sold.

AQR Capital Management first reported a position in CYCN in Q4 2019 and held it in 4 quarters. The position peaked at $466K in Q2 2020. 70 funds tracked by Wall St. Rank hold CYCN as of Q1 2021.

  • AQR Capital Management reported no remaining Cyclerion Therapeutics position as of Q1 2021 after selling out during the quarter.
  • AQR Capital Management sold 3,113 Cyclerion Therapeutics shares in Q1 2021, an estimated $191K.
  • AQR Capital Management first reported a position in Cyclerion Therapeutics in Q4 2019 and held it in 4 quarters.
  • AQR Capital Management's Cyclerion Therapeutics position peaked at $466K in Q2 2020.
  • 70 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2021.

Based on AQR Capital Management's 13F filing for Q1 2021, filed 17 May 2021.